Nottingham life sciences firm sold in £415m deal
Nottingham life sciences firm Albumedix has been bought by international counterpart Sartorius in a deal worth around £415m.
The Albumedix campus in Nottingham will become a manufacturing Centre of Excellence with the Sartorius group as part of the deal.
The acquisition will be carried out through Sartorius’ French listed subgroup Sartorius Stedim Biotech,
Jonas S. Møller, CEO of Albumedix, said: “We are delighted to be joining forces with Sartorius and look forward to accelerating our ambitious growth plans in delivering critical solutions to our global customers. We have been highly impressed with Sartorius’ knowledge and capabilities in the bioprocessing markets, and we are excited to join this purposeful journey. We believe Sartorius will bring tremendous value by strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform. We look forward to continuing our promise of empowering excellence in the life science industry.”
René Fáber, member of the executive board for the Bioprocess Solutions division of Sartorius, said: ““Albumedix will be an important addition to Sartorius’ advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials. This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones.”
William Blair acted as financial advisor to Albumedix, and Eversheds Sutherland provided legal advice. Milbank provided legal advice to Sartorius.